TNG456: Preclinical and Clinical Data for an MTAP-Deleted Cancer Treatment

1.8 KB of data describes the discovery of TNG456, a brain-penetrant PRMT5 inhibitor for cancers with MTAP loss. Homozygous deletion of the MTAP gene occurs in 10–15% of all human cancers and up to 50% of high-grade gliomas. The dataset, authored by Kevin M. Cottrell and last updated on 2026-05-18, relates to a compound currently in Phase I/II clinical studies.

Use Cases

• Analyzing the relationship between MTAP gene deletion and cancer susceptibility based on the described prevalence rates
• Modeling the pharmacokinetic properties of brain-penetrant inhibitors based on the mention of preclinical species data
• Studying the clinical development pathway for precision oncology drugs based on the Phase I/II trial status

Strengths

• Dataset is associated with a compound in active Phase I/II clinical trials, indicating real-world research relevance
• Description provides specific prevalence statistics for MTAP deletion (10–15% of all cancers, up to 50% in high-grade gliomas)

Limitations

• Dataset size is only 1.8 KB, indicating extremely limited scope and likely minimal records
• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment

Provenance

Source

Kevin M. Cottrell via figshare

Freshness

Last updated 2026-05-18 20:08:14; freshness should be verified